Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2003
10/14/2003US6632428 Hyperlipidemia, lowering both the serum cholesterol and serum triglyceride levels, culturing a Lovastatin-producing Monascus strain
10/14/2003US6632176 Products and methods for brachytherapy
10/14/2003CA2122911C 1,3-substituted cycloalkenes and cycloalkanes as central nervous system agents
10/09/2003WO2003083485A2 Protein for use in hypoxia related conditions
10/09/2003WO2003083135A2 Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)
10/09/2003WO2003083122A1 Treatment and prevention of angiostenosis
10/09/2003WO2003083105A1 Treatment and prevention of angiostenosis
10/09/2003WO2003083092A1 Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
10/09/2003WO2003083039A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/09/2003WO2003082918A1 Vegf peptides and their use
10/09/2003WO2003082893A2 Theraputic methods and uses of sapogenins and their derivatives
10/09/2003WO2003082874A2 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
10/09/2003WO2003082873A1 New-4-(pyrrolopyrimidin-6-yl)benzenesulphonamide derivatives
10/09/2003WO2003082872A1 Novel pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
10/09/2003WO2003082869A1 Azaindoles as inhibitors of c-jun n-terminal kinases
10/09/2003WO2003082868A1 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
10/09/2003WO2003082866A1 Polycyclic compounds as potent alpha2-adrenoceptor antagonists
10/09/2003WO2003082863A1 N-(morpholin-2yl) methyl acetamide derivatives as ccr-3 antagonists useful in the treatment of inflammatory diseases
10/09/2003WO2003082862A1 Anti-inflammatory morpholin-acetamide derivatives
10/09/2003WO2003082853A1 New compounds
10/09/2003WO2003082841A1 5-substituted 1,1-dioxo-`1,2,5!thiazolidine-3-one derivatives as ptpase 1b inhibitors
10/09/2003WO2003082837A1 Hydroxymorpholinone derivative and medicinal use thereof
10/09/2003WO2003082831A1 4-anilino quinazoline derivatives as antiproliferative agents
10/09/2003WO2003082829A1 New aryl imidazoles and related compounds as c5a receptor modulators
10/09/2003WO2003082827A1 Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents
10/09/2003WO2003082817A2 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
10/09/2003WO2003082813A2 Improvements in pharmaceutical compositions
10/09/2003WO2003082808A1 Benzamide derivatives
10/09/2003WO2003082807A2 Amino acids with affinity for the alpha-2-delta-protein
10/09/2003WO2003082802A1 Acid and ester compounds and methods of using the same
10/09/2003WO2003082798A1 Natural compounds and derivatives thereof for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications
10/09/2003WO2003082787A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
10/09/2003WO2003082350A2 Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
10/09/2003WO2003082324A1 Prevention and treatment of mycoplasma-associated diseases
10/09/2003WO2003082322A1 A method of modulating cellular activity
10/09/2003WO2003082320A1 Novel screening method
10/09/2003WO2003082318A1 Use of angiotensin 1-7 for enhancing cardiac function
10/09/2003WO2003082314A2 Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
10/09/2003WO2003082305A1 Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells
10/09/2003WO2003082296A1 Use of methylene blue and related compounds to prevent or reverse an exaggerated hemodynamic reaction
10/09/2003WO2003082280A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
10/09/2003WO2003082276A1 Antidiabetic agents
10/09/2003WO2003082274A1 Angiogenesis inhibitors
10/09/2003WO2003082271A2 Indole derivatives having anti-angiogenetic activity
10/09/2003WO2003082268A2 Hemiasterlin derivatives and uses thereof in the treatment of cancer
10/09/2003WO2003082259A1 Natural phenolic products and derivatives thereof for protection against neurodegenerative diseases
10/09/2003WO2003082207A2 Volume efficient controlled release dosage form
10/09/2003WO2003082205A2 Compounds and methods
10/09/2003WO2003082198A2 Methods of treatment with lxr modulators
10/09/2003WO2003082196A2 Combination therapy using trefoil peptides
10/09/2003WO2003082192A2 Certain pharmaceutically useful substituted aminoalkyl heterocycles
10/09/2003WO2003082191A2 Substituted 2,3-diphenyl pyridines
10/09/2003WO2003082190A2 Spirocyclic amides as cannabinoid receptor modulators
10/09/2003WO2003082189A2 Method for producing pseudo islets
10/09/2003WO2003045328A3 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof
10/09/2003WO2003016528A3 Oligonucleotide compositions and their use to induce apoptosis
10/09/2003WO2003016341A3 Regulation of iron uptake
10/09/2003WO2003007889A3 Therapeutic agents comprising pro-apoptotic proteins
10/09/2003WO2003005959A3 Amphiphilic star-like macromolecules for drug delivery
10/09/2003WO2003004040A8 Dietetic preparation with hypocholesterolemic activity
10/09/2003WO2002092004A3 Use of hmg fragment as anti-inflammatory agents
10/09/2003WO2002083627A3 Ligands des integrins avss6
10/09/2003WO2002078747A3 Pregabalin lactose conjugates
10/09/2003WO2002078682A3 Estrogen replacement therapy
10/09/2003WO2002077017A3 Medical uses of intercellular communication facilitating compounds
10/09/2003WO2002074056A3 Allosteric adenosine receptor modulators
10/09/2003WO2002069905A3 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
10/09/2003WO2002055063A3 Fumaric acid amides
10/09/2003WO2002047680A9 Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
10/09/2003WO2002033099A3 Human kinases
10/09/2003WO2002032449A3 Method for treating ischemic events affecting the central nervous system
10/09/2003WO2002026245A3 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
10/09/2003US20030191332 Prevention of neutrophil recruitment
10/09/2003US20030191308 Quinazoline compounds
10/09/2003US20030191291 Synthetic erythropoiesis stimulating proteins
10/09/2003US20030191285 Novel g protein-coupled receptor proteins and dnas thereof
10/09/2003US20030191278 Of given amino acid sequence; use as thrombolytic drugs and vasodilators
10/09/2003US20030191181 4-[(8-Ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome P450RAI inhibitory activity
10/09/2003US20030191178 Therapy for vision defects; hypotensive agents; respiratory system disorders
10/09/2003US20030191177 Maintenance dosage of beta blocker; cardiovascular disorders
10/09/2003US20030191175 Indole sPLA2 inhibitors
10/09/2003US20030191170 Central nervous system disorders; antiallergens; respiratory system disorders
10/09/2003US20030191163 Substituted cyclic amine metalloprotease inhibitors
10/09/2003US20030191153 Antithrombotic amides
10/09/2003US20030191136 Melanin concentrating hormone receptor ligands
10/09/2003US20030191132 Anticholesterol agents; cardiovascular disorders
10/09/2003US20030191126 Psychological disorders; antidepressants
10/09/2003US20030191123 2-amino-benzoxazinone derivatives for the treatment of obesity
10/09/2003US20030191122 Antidepressants; Alzheimer's disease; Parkinson's disease; central nervous system disorders
10/09/2003US20030191117 Acyclic piperazine and piperidine derivatives
10/09/2003US20030191111 Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
10/09/2003US20030191103 Hormone replacement therapy
10/09/2003US20030191098 Synergistic mixture of thalidomide antiinflammatory agnets
10/09/2003US20030191097 Hormone replacement therapy
10/09/2003US20030191092 MMP inhibitors
10/09/2003US20030191080 Cardiovascular disorders; hypotensive agents
10/09/2003US20030191074 Antibody therapy; immobilization
10/09/2003US20030191065 Insulin-like growth factor; genetic engineering; central nervous system disorders
10/09/2003US20030191057 Cardiovascular disorders; antiinflammatory agents
10/09/2003US20030191055 Inhibiting development of microvessels withins coronary or peripheral vessel walls for restenosis/atherosclerosis prevention or therapy
1 ... 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 ... 1595